Tivozanib in the treatment of renal cell carcinoma

@article{Hepgur2013TivozanibIT,
  title={Tivozanib in the treatment of renal cell carcinoma},
  author={Mehmet Hepgur and Sarmad Sadeghi and Tanya B. Dorff and David I. Quinn},
  journal={Biologics : Targets \& Therapy},
  year={2013},
  volume={7},
  pages={139 - 148}
}
Renal cell carcinoma (RCC) is an aggressive malignancy compared to other urological malignancies and has been associated with poor responses to conventional cytotoxic chemotherapy. Interferon-α and interleukin-2 were previously utilized in a limited number of patients with good performance status due to toxicity and safety issues. Over the last decade, through advances in the understanding of the biology and pathology of RCC, the important role of vascular endothelial growth factor (VEGF) in… 
Tivozanib: Status of Development
TLDR
In BATON-CRC trial, low-serum neuropilin-1 (NRP-1) levels were associated with better progression-free survival (PFS) in patients treated with tivozanib.
Resistance of renal cell carcinoma to targeted therapy
TLDR
The current challenges of drug resistance in the effective treatment of metastatic RCC with particular emphasis on targeted therapies are summarized.
Safety and Efficacy of Tivozanib in First-Line mRCC: A Multicenter Compassionate-Use Study (Meet-Uro 16)
TLDR
Tivozanib showed good activity and favorable safety profile in a real-world cohort of unselected patients with mRCC and predictive biomarkers of response to antiangiogenic therapy are urgently needed to identify RCC patients who could still receive a monotherapy with VEGFR inhibitors in the first line.
Novel anti-angiogenic therapeutic strategies in colorectal cancer
TLDR
This review is focused on the most recent clinical results of novel agents targeting VEGF and its receptors with a major focus on those investigated recently in clinical trials.
Optimizing treatment of renal cell carcinoma with VEGFR-TKIs: a comparison of clinical pharmacology and drug-drug interactions of anti-angiogenic drugs.
TLDR
The clinical pharmacology of selected VEGFR-TKIs used for the treatment of mRCC is described, highlighting the relevant differences; moreover the main pharmacologic characteristics of these drug are defined.
Efficacy of tivozanib treatment after sorafenib in patients with advanced renal cell carcinoma: crossover of a phase 3 study
TLDR
This crossover study of patients with advanced RCC demonstrated potent tivozanib anti-tumour activity and safety and tolerability profiles were acceptable and consistent with the established adverse event profile of tivzanib.
Radiotherapy and Renal Cell Carcinoma: A Continuing Saga
TLDR
Although renal cancer is traditionally considered radio-resistant, technological advances in the RT field with regards to modern linear accelerators, as well as advanced RT techniques have resulted in breakthrough therapeutic outcomes.
A novel personalized vaccine approach in combination with targeted therapy in advanced renal cell carcinoma.
TLDR
Vaccine-based immunotherapy represents a promising new approach for the treatment of patients with metastatic renal cell carcinoma; however, tumor-induced immunosuppression has limited the clinical efficacy of this modality until recently.
Sunitinib Versus Sorafenib as Initial Targeted Therapy for mCC-RCC With Favorable/Intermediate Risk: Multicenter Randomized Trial CROSS-J-RCC.
TLDR
The subgroup analysis revealed that the total PFS with SU/SO was superior to the totalPFS with SO/SU in the patients with favorable MSKCC risk and those with < 5 metastatic sites (SO/SU was superior for patients without previous nephrectomy).
Role of radiation therapy for renal tumors.
TLDR
The evidence with regards to the role of RT in primary RCC either as a primary treatment, adjuvant treatment, or preoperatively to improve resection outcomes is discussed.
...
1
2
...

References

SHOWING 1-10 OF 102 REFERENCES
Combination Therapy for Renal Cell Cancer: What Are Possible Options?
TLDR
Clinical benefit of antiangiogenic drugs in RCC has been heterogeneous, and in patients who do respond, benefits are modest and/or short-lived, and combination targeted therapy has been attempted, but with either very limited additional efficacy or nontolerable toxicities.
Immunotherapeutic strategies in kidney cancer—when TKIs are not enough
TLDR
It is proposed that a fundamental understanding of immunobiology in CC-RCC can improve the selection of patients for high-dose intravenous interleukin 2 and facilitate the development of novel immunotherapeutic strategies.
A phase III, randomized, controlled study to compare tivozanib with sorafenib in patients (pts) with advanced renal cell carcinoma (RCC).
TLDR
A phase III, randomized, controlled, global, multicenter trial is currently in progress to compare tivozanib with sorafenib in pts with advanced RCC, with a favorable safety profile and primary endpoint PFS by independent radiology review.
Novel Therapies for Metastatic Renal Cell Carcinoma: Efforts to Expand beyond the VEGF/mTOR Signaling Paradigm
TLDR
Novel immunotherapeutic strategies will be discussed, including vaccine therapy, cytotoxic T-lymphocyte antigen 4 (CTLA4) blockade, and programmed death-1 (PD-1) inhibition, as well as novel approaches to angiogenesis inhibition, such as abrogation of Ang/Tie-2 signaling.
Regorafenib for patients with previously untreated metastatic or unresectable renal-cell carcinoma: a single-group phase 2 trial.
TLDR
Regorafenib has antitumour activity as first-line treatment for metastatic or unresectable renal-cell carcinoma and the drug's safety profile requires close monitoring.
A phase I trial of combined tivozanib (AV-951) and temsirolimus therapy in patients (pts) with renal cell carcinoma (RCC).
TLDR
The combination of tivozanib with temsirolimus was well tolerated and showed clinical activity in patients with advanced RCC, including tumor responses in pts who had failed VEGF targeted therapies.
Vascular endothelial growth factor and mTOR pathways in renal cell carcinoma: differences and synergies of two targeted mechanisms
TLDR
The mechanistic distinctions and functional overlaps of these classes of agents are assessed, and key characteristics of their respective clinical efficacy and side‐effect profiles in patients with RCC are discussed, some of which might affect patient selection and treatment strategies.
Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma.
TLDR
IL-8 is revealed as an important contributor to sunitinib resistance in ccRCC and a candidate therapeutic target to reverse acquired or intrinsic resistance to sun itinib in this malignancy.
Tivozanib: current status and future directions in the treatment of solid tumors
TLDR
The current review will outline the development pathway of tivozanib to date, and offer lessons learned and future opportunities to distinguish this agent among other VEGF-TKIs.
Phase Ib study of tivozanib (AV-951) in combination with temsirolimus in patients with renal cell carcinoma.
TLDR
Combination of tivozanib plus temsirolimus demonstrated acceptable tolerability and suggested no synergistic toxicity and the observed clinical activity and manageable toxicity profile of this combination warrant further exploration in patients with RCC.
...
1
2
3
4
5
...